Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases

doi:10.19803/j.1672-8629.20230467

Abstract

Abstract: Objective To analyze the characteristics and patterns of adverse drug reactions (ADR) induced by antineoplastic medications, and to provide reference for ensuring the safety of ambulatory chemotherapy. Methods A total of 613 reports about ADR caused by antineoplastic drugs between 2021 and 2022 in our hospital were collected and analyzed. Results Among the 613 cases of ADR, 60.03% occurred inside the hospital. Male patients outnumbered female ones and most of the patients ranged from 51 to 70 in age (51.23%). ADR were caused by intravenous infusion in 72.49% of these cases, 14.68% were severe ones, and 4.24% failed to improve after medication withdrawal or treatment. Cytotoxic anti-tumor medicines were responsible for 81.23% of these ADR, with oxaliplatin accounting for 18.65%. The blood or hematopoietic system was responsible for the largest number of ADR (17.68%). Conclusion ADR induced by cytotoxic anticancer drugs should be monitored, with particular attention to special populations and key drugs. When anticancer drugs are used in an ambulatory chemotherapy center, the risk of ADR should be assessed and corresponding treatment plans should be made to ensure the safety of patients.

Key words: antineoplastic drug, novel anti-tumor drug, adverse drug reaction, safe medication, daytime chemotherapy, elderly patients

CLC Number:

R916.696

HUANG Huanjun, MAI Jiaheng, ZHANG Yunhui, GUO Chenchen, LIANG Weiting. Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 324-328.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230467

https://www.zgywjj.com/EN/Y2024/V21/I3/324

References

[1] LIU LJ.Breast cancer has become the most common cancer in the world[J]. Chinese Journal of Breast Disease (Electronic Edition)(中华乳腺病杂志电子版), 2020, 14(6): 389-389.
[2] National Health Commission of the People’s Republic of China. Guidelines for the clinical use of new antineoplastic drugs (2022 edition)[R/OL]. (2022-12-30)[2023-07-20]. http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
[3] ZHENG RS, ZHANG SW, ZENG HM, et al.Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[4] WANG NN, BAI Y, LIU H, et al.Characteristics of adverse reactions of antineoplastic drugs in 787 cases and the prognosis analysis[J]. Anti-tumor Pharmacy(肿瘤药学), 2019, 9(1): 143-148.
[5] YAN J, XU F, ZHAO J.Clinical efficacy of vincristine cyclophosphamide sequential therapy for malignant lymphoma[J]. The Practical Journal of Cancer(实用癌症杂志), 2016, 31(7): 1199-1201.
[6] ZHANG XM, XIA YC, YANG J, et al.Adverse reactions of platinum-based anticancer drugs in a level a tertiary general hospital in 2020[J]. Journal of Cancer Control and Treatment(肿瘤预防与治疗), 2022, 35(8): 726-730.
[7] Chinese Society of Liver Cancer, China Anti-Cancer Association. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition)[J]. Chinese Journal of Digestive Surgery(中华消化外科杂志), 2021, 20(7): 754-759.
[8] LYU N, KONG YN, MU LW, et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs sorafenib for advanced hepatocellular carcinoma[J]. Journal of Hepatology, 2018, 69(1): 60-69.
[9] HE MK, LI QJ, ZOU RH, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion a randomized clinical trial[J]. Jama Oncology, 2019, 5(7): 953-960
[10] JI SY.Analysis of influencing factors of adverse reactions in patients treated with traditional Chinese medicine injection[J]. Medical Journal of Chinese People’s Health(中国民康医学), 2022, 34(23): 1-4.
[11] WANG D, MO TX, LI CX, et al.Research on construction of quality and safety evaluation index system of ambulatory chemotherapy service[J]. Chinese Hospital Management(中国医院管理), 2023, 43(3): 51-54.
[12] TANG LN, ZHOU XW, DONG LL et al. Analysis of 533 cases of adverse drug reactions induced by antineoplastic drugs[J]. Anti-tumor Pharmacy(肿瘤药学), 2022, 12(5): 663-670.
[13] ZHAO YW, WANG LL, SHI HY.Study on adverse reactions of platinum-based antitumor drugs in a hospital[J]. China Medicine and Pharmacy(中国医药科学), 2022, 12(24): 84-86, 137.
[14] LUO SS, QU J, ZHOU N, et al.289 cases of adverse drug reactions associated with monoclonal antibody antitumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(4): 444-448.
[15] LI CX, WANG D, MO TX, et al.Study on the current situation of daycare chemotherapy in China[J]. Chinese Hospital Management(中国医院管理), 2022, 42(2): 47-49.